Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501121 | 0.89 | HRH1 (0.58) | HRH3L3MBTL1SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL5510481 | 0.85 | AOC3 (0.55) | L3MBTL3SIGMAR1CA2 | |
| SCHEMBL6644138 | 0.83 | HRH3 (0.58) | HRH3L3MBTL1MBTD1L3MBTL3SLC6A3 | |
| SCHEMBL6223200 | 0.82 | HRH3 (0.61) | HRH3L3MBTL1MBTD1L3MBTL3CA2 | |
| SCHEMBL2761915 | 0.81 | HRH3 (0.61) | HRH3L3MBTL1MBTD1L3MBTL3SLC6A3 | |
| SCHEMBL2762023 | 0.81 | HRH3 (0.61) | HRH3L3MBTL1MBTD1L3MBTL3SLC6A3 | |
| SCHEMBL7453093 | 0.79 | HRH3 (0.61) | HRH3L3MBTL1MBTD1L3MBTL3SLC6A3 | |
| SCHEMBL6224393 | 0.79 | HRH3 (0.55) | HRH3L3MBTL1MBTD1L3MBTL3CA2 | |
| SCHEMBL5505020 | 0.78 | SIGMAR1 (0.54) | SIGMAR1KCNJ1HRH1 | |
| SCHEMBL3782542 | 0.77 | HRH3 (0.68) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |